Ternel

Ternel is a France-based early-stage venture firm whose public footprint suggests a generalist seed and pre-Series A focus across software and technology themes, with limited specific data from the inputs provided on healthcare specialization, AI emphasis, or exact check size. Firms in this profile typically deploy checks in the range of two hundred fifty thousand to one and a half million euros at seed, with the ability to follow on selectively in subsequent rounds. The natural fit is a focused French or European seed company with a defined product, early commercial signals or strong founder credibility, and ambitions to scale across the European continent. Healthcare AI founders can engage if the company is fundamentally software-led with a clear commercial wedge into European healthcare buyers, particularly in markets where French or broader European regulatory and reimbursement dynamics matter. Companies building therapeutics, complex devices, or pure consumer health products without enterprise dynamics are unlikely to find specialist value here. Founders should not expect deep healthcare regulatory or clinical coaching from a generalist French seed firm, but should value the regional network access and the credibility a regional seed lead provides for subsequent fundraising. The best entry path is a warm introduction from a portfolio CEO, a French operator, or a fellow European seed investor. Direct outreach to partners via LinkedIn or the firm’s website is acceptable for cold contact, paired with a tight executive summary, evidence of European commercial traction, and a clear articulation of why the firm adds value beyond capital.